367 related articles for article (PubMed ID: 31795192)
1. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
Li H; Zhang J; Tong JHM; Chan AWH; Yu J; Kang W; To KF
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795192
[TBL] [Abstract][Full Text] [Related]
2. Different mutation profiles associated to P53 accumulation in colorectal cancer.
López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
4. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
5. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
Li XL; Zhou J; Chen ZR; Chng WJ
World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
[TBL] [Abstract][Full Text] [Related]
6. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors.
Sakai E; Fukuyo M; Matsusaka K; Ohata K; Doi N; Takane K; Matsuhashi N; Fukushima J; Nakajima A; Kaneda A
Cancer Sci; 2016 Jun; 107(6):820-7. PubMed ID: 26991699
[TBL] [Abstract][Full Text] [Related]
8. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
[TBL] [Abstract][Full Text] [Related]
9. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
Alam SK; Yadav VK; Bajaj S; Datta A; Dutta SK; Bhattacharyya M; Bhattacharya S; Debnath S; Roy S; Boardman LA; Smyrk TC; Molina JR; Chakrabarti S; Chowdhury S; Mukhopadhyay D; Roychoudhury S
Cell Death Differ; 2016 Apr; 23(4):707-22. PubMed ID: 26494468
[TBL] [Abstract][Full Text] [Related]
10. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
11. miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53.
Wang L; Yu P
Oncol Rep; 2016 Dec; 36(6):3225-3232. PubMed ID: 27779716
[TBL] [Abstract][Full Text] [Related]
12. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
Iacopetta B; Russo A; Bazan V; Dardanoni G; Gebbia N; Soussi T; Kerr D; Elsaleh H; Soong R; Kandioler D; Janschek E; Kappel S; Lung M; Leung CS; Ko JM; Yuen S; Ho J; Leung SY; Crapez E; Duffour J; Ychou M; Leahy DT; O'Donoghue DP; Agnese V; Cascio S; Di Fede G; Chieco-Bianchi L; Bertorelle R; Belluco C; Giaretti W; Castagnola P; Ricevuto E; Ficorella C; Bosari S; Arizzi CD; Miyaki M; Onda M; Kampman E; Diergaarde B; Royds J; Lothe RA; Diep CB; Meling GI; Ostrowski J; Trzeciak L; Guzinska-Ustymowicz K; Zalewski B; Capellá GM; Moreno V; Peinado MA; Lönnroth C; Lundholm K; Sun XF; Jansson A; Bouzourene H; Hsieh LL; Tang R; Smith DR; Allen-Mersh TG; Khan ZA; Shorthouse AJ; Silverman ML; Kato S; Ishioka C;
Ann Oncol; 2006 May; 17(5):842-7. PubMed ID: 16524972
[TBL] [Abstract][Full Text] [Related]
13. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
Hassin O; Nataraj NB; Shreberk-Shaked M; Aylon Y; Yaeger R; Fontemaggi G; Mukherjee S; Maddalena M; Avioz A; Iancu O; Mallel G; Gershoni A; Grosheva I; Feldmesser E; Ben-Dor S; Golani O; Hendel A; Blandino G; Kelsen D; Yarden Y; Oren M
Nat Commun; 2022 May; 13(1):2800. PubMed ID: 35589715
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
15. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
16. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
[TBL] [Abstract][Full Text] [Related]
17. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues
Xue Y; Barker N; Hoon S; He P; Thakur T; Abdeen SR; Maruthappan P; Ghadessy FJ; Lane DP
Cancer Res; 2019 Jul; 79(14):3595-3607. PubMed ID: 31138526
[TBL] [Abstract][Full Text] [Related]
19. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
[TBL] [Abstract][Full Text] [Related]
20. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
Choi TG; Nguyen MN; Kim J; Jo YH; Jang M; Nguyen NNY; Yun HR; Choe W; Kang I; Ha J; Tang DG; Kim SS
J Pathol; 2018 Sep; 246(1):115-126. PubMed ID: 29876924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
